In addition to ActiveCare+S.F.T.®, MCS is targeting several new breakthrough applications:
-
The ActiveCare S.F.T. ® Prevention-Detection
This device represents the third generation of the ActiveCare
® product line, which is targeted at the DVT prevention field. This system will make use of the continuously flowing information, generated by the SFT sensors to identify proximal venous flow obstruction. The development of this new device aims to provide a unique combination of treatment and detection capabilities, having the potential to further upgrade DVT prophylaxis and treatment and create new standards of care in this field.
-
The ActiveCast™
Bone fracture of the lower extremity is associated with post-traumatic pain and edema, impaired venous function, high risk for DVT and substantial risk for delayed healing and prolonged rehabilitation. The development of this new device has the potential to turn the standard stabilizing cast, which is a passive device, into an active system that will reduce posttraumatic edema and DVT and will enhance fracture healing and patient rehabilitation.
-
The ActiveCareVascular™
This device is targeted at the outpatient wound care market. Chronic leg ulcers are estimated to affect about two percent of the western population. Venous ulcers are the leading cause of leg ulceration (75-90%).
Chronic wounds exhibit an imbalance between tissue deposition stimulated by GFs and tissue destruction mediated mainly by MMPs. It was found that the normal balance between these two activities is impaired in NO deficiency, and that mechanical devices can reverse the imbalance, mainly by increasing the NO and GF synthesis. The treatment was found to be effective in venous, arterial, diabetic and mixed type wounds. Sporadic case studies, in which the ActiveCare Vascular™ device was used, revealed encouraging results.